Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial Evaluating Fixed Dose and Faster Ramp-up of Epcoritamab With Lenalidomide for 3L Relapse/Refractory Large B-cell Lymphoma After CAR T-cells Therapy in 2nd Line

NCT07814001 is registered in ClinicalTrials.gov with The Lymphoma Academic Research Organisation as lead sponsor.

NCT NCT07814001
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07814001 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial Evaluating Fixed Dose and Faster Ramp-up of Epcoritamab With Lenalidomide for 3L Relapse/Refractory Large B-cell Lymphoma After CAR T-cells Therapy in 2nd Line
Lead sponsor
The Lymphoma Academic Research Organisation
Phase
Phase 2
Overall status
Not yet recruiting
Start date
December 31, 2026
Completion date
May 31, 2031
Enrollment
55 (estimated)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

refractory diffuse large b-cell lymphoma (dlbcl), refractory follicular lymphoma grade 3b, refractory high-grade b-cell lymphoma, refractory large b-cell lymphoma (lbcl), refractory t-cell/histiocyte-rich large b-cell lymphoma, refractory transformed follicular lymphoma